Elekta Continues to Grow in Key Emerging Markets Delivers Clinical Solutions to Nine Cancer Clinics in Russia

Elekta is improving the availability of cancer care for Russian patients by
delivering clinical solutions, services and training to a number of key
hospitals and cancer centers throughout Russia
STOCKHOLM, Sweden--(Business Wire)--
Regulatory News:

Elekta (STO:EKTAB) has won seven out of ten tenders being part of the new
Russian National Oncology Program. The program was initiated under the auspices
of Prime Minister Vladimir Putin in early 2009 with the aim to improve
prevention and early detection of cancer.

Currently, patients in Russia are diagnosed with cancer mostly at stages III and
IV, negatively affecting the survival rate and with expensive medical and drug
treatment required. The program is considered an important step by the Russian
Government to increase the life span for the Russian people.

"By 2012, the situation must be changed so that identification and treatment of
cancer patients will already happen at stages I and II of the disease," said the
Russian Minister of Health, Tatiana Golikova at the presentation of the program.

As part of the program, Elekta will deliver four Elekta Synergy, two Precise
Treatment System and one Elekta Axesse to hospitals and cancer centers
throughout the country. Engineers and medical physicists from Elekta and its
Russian distributor MSM-Medimpex will provide training for all medical staff as
well as services.

In addition, two other key centers in Russia recently purchased two Elekta
Axesse for their stereotactic program.

"We are proud to be a part of the expansion of cancer care in Russia, and in
making the latest clinical treatment solutions available to more patients
throughout the country," says Olof Sandén, Executive Vice President for Elekta
Europe, Africa, Latin America and Middle East.

Elekta is continuing to execute on its plan for geographical expansion in key
emerging markets, where Russia is one of several geographical areas with a large
unmet need for cancer care.

"We have created a new structure and strategies supporting our focus on emerging
markets where a large number of patients can benefit from life-saving
technologies at an affordable cost per patient", says Mr. Sandén.

About Elekta

Elekta is a human care company pioneering significant innovations and clinical
solutions for treating cancer and brain disorders. The company develops
sophisticated state of the art tools and treatment planning systems for
radiation therapy and radiosurgery, as well as workflow enhancing software
systems across the spectrum of cancer care.

Stretching the boundaries of science and technology, providing intelligent and
resource-efficient solutions that offer confidence to both healthcare providers
and patients, Elekta aims to improve, prolong and even save patient lives,
making the future possible today.

Today, Elekta solutions in oncology and neurosurgery are used in over 5,000
hospitals globally, and every day more than 100,000 patients receive diagnosis,
treatment or follow-up with the help of a solution from the Elekta Group.

Elekta employs around 2,500 employees globally. The corporate headquarter is
located in Stockholm, Sweden, and the company is listed on the Nordic Exchange
under the ticker EKTAb. For more information about Elekta, please visit
www.elekta.com.

This information was brought to you by Cision http://www.cisionwire.com.

Elekta AB
Stina Thorman, Investor Relations
Tel: +46 8 587 254 37, +46 70 778 60 10
e-mail: stina.thorman@elekta.com
or
Elekta Inc.
Michelle Lee, Director, Marketing Services
Tel: +1 770-670-2447
e-mail: michelle.lee@elekta.com

Copyright Business Wire 2009